Enodia Therapeutics acquired Kezar Life Sciences’ Sec61‑based discovery and development assets in a deal that pays Kezar $1 million upfront and up to $127 million in development, regulatory and commercial milestones, plus tiered royalties. Enodia said the acquisition strengthens its selective Sec61 modulation platform and adds Kezar’s preclinical datasets, proteomics, cryo‑EM insights and tailored cell libraries. Kezar will retain conviction in Sec61 biology but will transition the specific program to Enodia, which plans to integrate the assets to accelerate selective targeted protein degradation approaches. The transaction highlights continued consolidation in the targeted protein degradation field and underscores industry interest in Sec61 as a mechanism to prevent synthesis of pathogenic secreted and membrane proteins.